MX2022001186A - Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo. - Google Patents

Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo.

Info

Publication number
MX2022001186A
MX2022001186A MX2022001186A MX2022001186A MX2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A
Authority
MX
Mexico
Prior art keywords
nitenin
treatment
sup
sub
compounds
Prior art date
Application number
MX2022001186A
Other languages
English (en)
Inventor
Santos Baltazar De Lima Pedro Afonso Dos
Dos Santos Beatriz Szwarc
Abreu Ana Rosa Maço
Bastos André Emanuel Pinheiro
Rui Gomes
De Sousa Marisa Isabel Lopes
Serrão Joana Maria Monteiro
Lino Sílvia Patrícia Pena
Silveira Máximo Patrícia Isabel Da
Ferreira Luísa Maria Pinto
Sério Branco Paula Cristina De
Mourão Henrique Sovela
Sabino Vanessa Alexandra Rosado
Tong Ming Him
Laurent Alain Claudetrembleau
Da Costa Lourenço Ana Maria Ferreira
Mondragão Miguel Angelo Segão
Original Assignee
Sea4Us Biotecnologia E Recursos Marinhos Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea4Us Biotecnologia E Recursos Marinhos Lda filed Critical Sea4Us Biotecnologia E Recursos Marinhos Lda
Publication of MX2022001186A publication Critical patent/MX2022001186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/36—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a compuestos análogos de nitenina (de fórmulas I, II, III y IV) y su uso como agente farmacéutico en el tratamiento, prevención o reducción de dolor tanto agudo como crónico. El modo de acción descrito en la presente permite que los compuestos de nitenina y de análogos de nitenina actúen como analgésicos a través de la reducción de corrientes K+ en lugar de su potenciación. Con relación a su alta eficacia en el tratamiento del dolor, estos compuestos son sumamente selectivos para corrientes de potasio activadas por voltaje lentas (K+) expresadas en neuronas de la raíz dorsal de diámetro pequeño (sDRGn), principalmente en las mediadas por el canal de potasio dependiente de voltaje (Kv), Kv1.3. Tales hallazgos, junto con aquellos que demuestran que los compuestos de nitenina y de análogos de nitenina actúan como bloqueadores dependientes de la actividad también conducen a efectos secundarios muy reducidos. Los resultados descritos en la presente muestran que los compuestos de nitenina y de análogos de nitenina descritos en la presente son una alternativa viable para los compuestos farmacéuticos que ya existen que se usan en el tratamiento del dolor.
MX2022001186A 2019-07-31 2020-07-22 Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo. MX2022001186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT11568519 2019-07-31
PCT/IB2020/056915 WO2021019373A1 (en) 2019-07-31 2020-07-22 Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Publications (1)

Publication Number Publication Date
MX2022001186A true MX2022001186A (es) 2022-05-11

Family

ID=72240450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001186A MX2022001186A (es) 2019-07-31 2020-07-22 Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo.

Country Status (10)

Country Link
US (1) US20220288017A1 (es)
EP (1) EP4003984A1 (es)
JP (1) JP2022544057A (es)
CN (1) CN114616230A (es)
AU (1) AU2020320115A1 (es)
CA (1) CA3149175A1 (es)
IL (1) IL290192A (es)
MX (1) MX2022001186A (es)
WO (1) WO2021019373A1 (es)
ZA (1) ZA202201154B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116115739B (zh) * 2022-12-29 2024-01-09 天津市肿瘤医院（天津医科大学肿瘤医院） 胃动素及其受体激动剂的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
EP3126831A1 (en) * 2014-04-01 2017-02-08 The Procter & Gamble Company Method for screening trp channels
CN106146530A (zh) * 2015-04-14 2016-11-23 中国科学院生态环境研究中心 一种合成cephalosporolides E,F,H,I的新方法

Also Published As

Publication number Publication date
CA3149175A1 (en) 2021-02-04
ZA202201154B (en) 2024-02-28
WO2021019373A4 (en) 2021-03-25
JP2022544057A (ja) 2022-10-17
CN114616230A (zh) 2022-06-10
AU2020320115A1 (en) 2022-02-24
EP4003984A1 (en) 2022-06-01
WO2021019373A1 (en) 2021-02-04
IL290192A (en) 2022-03-01
US20220288017A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
EP2512479A4 (en) METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE
MY196370A (en) Synergistic Compositions Of Bioactive Agents For Optimizing Cellular Health
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
MX2021008974A (es) Tratamiento para los trastornos de la piel con composiciones combinadas tópicas de tapinarof.
GEP20247585B (en) Furoindazole derivatives
EP4241855A3 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
ZA202201154B (en) Nitenin analogue compounds and their use in the treatment of chronic and acute pain
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2023003725A (es) Composiciones farmacéuticas y usos de las mismas para la prevención y/o tratamiento de la inflamación.
MX2018007377A (es) Composicion de acido hialuronico para inyecciones en el pene.